Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases

Science Translational Medicine

Volumn 8, Issue 360, 2016, Pages

  Rahbari, Nuh N ^a,b,e   Kedrin, Dmitriy ^a   Incio, Joao ^a   Liu, Hao ^a   Ho, William W ^a,c   Nia, Hadi T ^a   Edrich, Christina M ^a   Jung, Keehoon ^a   Daubriac, Julien ^a   Chen, Ivy ^a,d   Heishi, Takahiro ^a   Martin, John D ^a   Huang, Yuhui ^a,f   Maimon, Nir ^a   Reissfelder, Christoph ^b   Weitz, Jurgen ^b   Boucher, Yves ^a   Clark, Jeffrey W ^a   Grodzinsky, Alan J ^c   Duda, Dan G ^a   Jain, Rakesh K ^a   Fukumura, Dai ^a   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c Massachusetts Institute of Technology Cambridge   (United States)

^d HARVARD UNIVERSITY   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; BEVACIZUMAB; COLLAGEN; FLUOROURACIL; FOLINIC ACID; GLYCOSAMINOGLYCAN POLYSULFATE; HYALURONIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B20.4 1.1; OXALIPLATIN; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; A73025; GLYCOSAMINOGLYCAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HUMAN; HUMAN TISSUE; HYPOXIA; LIVER METASTASIS; LIVER PERFUSION; METASTASIS RESECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR ASSOCIATED LEUKOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOMECHANICS; C57BL MOUSE; COLORECTAL TUMOR; DRUG RESISTANCE; LIVER TUMOR; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SECONDARY; TRANSLATIONAL RESEARCH; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; BEVACIZUMAB; BIOMECHANICAL PHENOMENA; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR MATRIX; GLYCOSAMINOGLYCANS; HUMANS; HYALURONIC ACID; HYPOXIA; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; TRANSLATIONAL MEDICAL RESEARCH; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84991795131     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaf5219     Document Type: Article

References (78)

1. R. K. Jain, The next frontier of molecular medicine: Delivery of therapeutics. Nat. Med. 4, 655-657 (1998).
2. V. P. Chauhan, T. Stylianopoulos, Y. Boucher, R. K. Jain, Delivery of molecular and nanoscale medicine to tumors: Transport barriers and strategies. Annu. Rev. Chem. Biomol. Eng. 2, 281-298 (2011).
3. R. K. Jain, Normalizing tumor microenvironment to treat cancer: Bench to bedside to biomarkers. J. Clin. Oncol. 31, 2205-2218 (2013).
4. V. P. Chauhan, R. K. Jain, Strategies for advancing cancer nanomedicine. Nat. Mater. 12, 958-962 (2013).
5. T. Stylianopoulos, J. D. Martin, M. Snuderl, F. Mpekris, S. R. Jain, R. K. Jain, Coevolution of solid stress and interstitial fluid pressure in tumors during progression: Implications for vascular collapse. Cancer Res. 73, 3833-3841 (2013).
6. T. Stylianopoulos, J. D. Martin, V. P. Chauhan, S. R. Jain, B. Diop-Frimpong, N. Bardeesy, B. L. Smith, C. R. Ferrone, F. J. Hornicek, Y. Boucher, L. L. Munn, R. K. Jain, Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc. Natl. Acad. Sci. U.S.A. 109, 15101-15108 (2012).
7. R. K. Jain, Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia. Cancer Cell 26, 605-622 (2014).
8. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross, F. Kabbinavar, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004).
9. P. Carmeliet, R. K. Jain, Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298-307 (2011).
10. K. Y. Aguilera, L. B. Rivera, H. Hur, J. G. Carbon, J. E. Toombs, C. D. Goldstein, M. T. Dellinger, D. H. Castrillon, R. A. Brekken, Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma. Cancer Res. 74, 1032-1044 (2014).
11. Y. Chen, Y. Chen, Y. Huang, T. Reiberger, A. M. Duyverman, P. Huang, R. Samuel, L. Hiddingh, S. Roberge, C. Koppel, G. Y. Lauwers, A. X. Zhu, R. K. Jain, D. G. Duda, Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromalderived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigenpositive myeloid cell infiltration in mice. Hepatology 59, 1435-1447 (2014).
12. P. P. Provenzano, C. Cuevas, A. E. Chang, V. K. Goel, D. D. Von Hoff, S. R. Hingorani, Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21, 418-429 (2012).
13. A. Kultti, X. Li, P. Jiang, C. B. Thompson, G. I. Frost, H. M. Shepard, Therapeutic targeting of hyaluronan in the tumor stroma. Cancers 4, 873-903 (2012).
14. C. J. Whatcott, H. Han, R. G. Posner, G. Hostetter, D. D. Von Hoff, Targeting the tumor microenvironment in cancer: Why hyaluronidase deserves a second look. Cancer Discov. 1, 291-296 (2011).
15. V. P. Chauhan, Y. Boucher, C. R. Ferrone, S. Roberge, J. D. Martin, T. Stylianopoulos, N. Bardeesy, R. A. DePinho, T. P. Padera, L. L. Munn, R. K. Jain, Compression of pancreatic tumor blood vessels by hyaluronan is caused by solid stress and not interstitial fluid pressure. Cancer Cell 26, 14-15 (2014).
16. C. J. Whatcott, C. H. Diep, P. Jiang, A. Watanabe, J. LoBello, C. Sima, G. Hostetter, H. M. Shepard, D. D. Von Hoff, H. Han, Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer. Clin. Cancer Res. 21, 3561-3568 (2015).
17. M. Morimoto-Tomita, Y. Ohashi, A. Matsubara, M. Tsuiji, T. Irimura, Mouse colon carcinoma cells established for high incidence of experimental hepatic metastasis exhibit accelerated and anchorage-independent growth. Clin. Exp. Metastasis 22, 513-521 (2005).
18. D. P. Griswold, T. H. Corbett, A colon tumor model for anticancer agent evaluation. Cancer 36, 2441-2444 (1975).
19. W.-C. Liang, X. Wu, F. V. Peale, C. V. Lee, Y. G. Meng, J. Gutierrez, L. Fu, A. K. Malik, H.-P. Gerber, N. Ferrara, G. Fuh, Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J. Biol. Chem. 281, 951-961 (2006).
20. D. A. Wicherts, R. J. de Haas, M. Sebagh, E. S. Corrales, D. L. Gorden, F. Lévi, B. Paule, D. Azoulay, D. Castaing, R. Adam, Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases. Br. J. Surg. 98, 399-407 (2011).
21. T. Cotechini, T. R. Medler, L. M. Coussens, Myeloid cells as targets for therapy in solid tumors. Cancer J. 21, 343-350 (2015).
22. B. Ruffell, L. M. Coussens, Macrophages and therapeutic resistance in cancer. Cancer Cell 27, 462-472 (2015).
23. D. Hanahan, L. M. Coussens, Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309-322 (2012).
24. K. R. Karlmark, R. Weiskirchen, H. W. Zimmerman, N. Gassler, F. Ginhoux, C. Weber, M. Merad, T. Luedde, C. Trautwein, Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology 50, 261-274 (2009).
25. V. Cortez-Retamozo, M. Etzrodt, I. Newton, P. J. Rauch, A. Chudnovskiy, C. Berger, R. J. H. Ryan, Y. Iwamoto, B. Marinelli, R. Gorbatov, R. Forghani, T. I. Novobrantsev, V. Koteliansky, J.-L. Figueireod, J. W. Chen, D. G. Anderson, M. Nahrendorf, F. K. Swirski, R. Weissleder, M. J. Pittet, Origins of tumor-Associated macrophages and neutrophils. Proc. Natl. Acad. Sci. U.S.A. 109, 2491-2496 (2012).
26. F. K. Swirski, M. Nahrendorf, M. Etzrodt, M. Wildgruber, V. Cortez-Retamozo, P. Panizzi, J.-L. Figueiredo, R. H. Kohler, A. Chudnovskiy, P. Waterman, E. Aikawa, T. R. Mempel, P. Libby, R. Weissleder, M. J. Pittet, Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325, 612-616 (2009).
27. V. P. Chauhan, J. D. Martin, H. Liu, D. A. Lacorre, S. R. Jain, S. V. Kozin, T. Stylianopoulos, A. S. MoUSA, X. Han, P. Adstamongkonkul, Z. Popovic, P. Huang, M. G. Bawendi, Y. Boucher, R. K. Jain, Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat. Commun. 4, 2516 (2013).
28. B. Diop-Frimpong, V. P. Chauhan, S. Krane, Y. Boucher, R. K. Jain, Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc. Natl. Acad. Sci. U.S.A. 108, 2909-2914 (2011).
29. S. L. Friedman, Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver. Physiol. Rev. 88, 125-172 (2008).
30. N. C. Singha, T. Nekoroski, C. Zhao, R. Symons, P. Jiang, G. I. Frost, Z. Huang, H. M. Shepard, Tumor-Associated hyaluronan limits efficacy of monoclonal antibody therapy. Mol. Cancer Ther. 14, 523-532 (2015).
31. Y. Huang, J. Yuan, E. Righi, W. S. Kamoun, M. Ancukiewicz, J. Nezivar, M. Santosuosso, J. D. Martin, M. R. Martin, F. Vianello, P. Leblan, L. L. Munn, P. Huang, D. G. Duda, D. Fukumura, R. K. Jain, M. C. Poznansky, Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl. Acad. Sci. U.S.A. 109, 17561-17566 (2012).
32. J. H. Strickler, H. I. Hurwitz, Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. Oncologist 17, 513-524 (2012).
33. J. Welti, S. Loges, S. Dimmeler, P. Carmeliet, Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J. Clin. Invest. 123, 3190-3200 (2013).
34. G. L. Semenza, Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu. Rev. Pathol. 9, 47-71 (2014).
35. A. Casazza, G. Di Conza, M. Wenes, V. Finisguerra, S. Deschoemaeker, M. Mazzone, Tumor stroma: A complexity dictated by the hypoxic tumor microenvironment. Oncogene 33, 1743-1754 (2014).
36. G. T. Motz, G. Coukos, Deciphering and reversing tumor immune suppression. Immunity 39, 61-73 (2013).
37. R. Noy, J. W. Pollard, Tumor-Associated macrophages: From mechanisms to therapy. Immunity 41, 49-61 (2014).
38. W. R. Wilson, M. P. Hay, Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 11, 393-410 (2011).
39. A. Palazón, J. Aragonés, A. Morales-Kastresana, M. O. de Landázuri, I. Melero, Molecular pathways: Hypoxia response in immune cells fighting or promoting cancer. Clin. Cancer Res. 18, 1207-1213 (2012).
40. D. F. Higgins, K. Kimura, W. M. Bernhardt, N. Shrimanker, Y. Akai, B. Hohenstein, Y. Saito, R. S. Johnson, M. Kretzler, C. D. Cohen, K.-U. Eckardt, M. Iwano, V. H. Haase, Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-To-mesenchymal transition. J. Clin. Invest. 117, 3810-3820 (2007).
41. F. Shojaei, X. Wu, A. K. Malik, C. Zhong, M. E. Baldwin, S. Schanz, G. Fuh, H.-P. Gerber, N. Ferrara, Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 25, 911-920 (2007).
42. Y. Chen, R. R. Ramjiawan, T. Reiberger, M. R. Ng, T. Hato, Y. Huang, H. Ochiai, S. Kitahara, E. C. Unan, T. P. Reddy, C. Fan, P. Huang, N. Bardeesy, A. X. Zhu, R. K. Jain, D. G. Duda, CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-Treated hepatocellular carcinoma in mice. Hepatology 61, 1591-1602 (2015).
43. M. A. Jacobetz, D. S. Chan, A. Neesse, T. E. Bapiro, N. Cook, K. K. Frese, C. Feig, T. Nakagawa, M. E. Caldwell, H. I. Zecchini, M. P. Lolkema, P. Jiang, A. Kultti, C. B. Thompson, D. C. Maneval, D. I. Jodrell, G. I. Frost, H. M. Shepard, J. N. Skepper, D. A. Tuveson, Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 62, 112-120 (2013).
44. C. B. Thompson, H. M. Shepard, P. M. O'Connor, S. Kadhim, P. Jiang, R. J. Osgood, L. H. Bookbinder, X. Li, B. J. Sugarman, R. J. Connor, S. Nadjsombati, G. I. Frost, Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol. Cancer Ther. 9, 3052-3064 (2010).
45. R. K. Jain, T. Stylianopoulos, Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 7, 653-664 (2010).
46. R. K. Jain, Transport of molecules in the tumor interstitium: A review. Cancer Res. 47, 3039-3051 (1987).
47. H. F. Dvorak, Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315, 1650-1659 (1986).
48. G. Alexandrakis, E. B. Brown, R. T. Tong, T. D. McKee, R. B. Campbell, Y. Boucher, R. K. Jain, Two-photon fluorescence correlation microscopy reveals the two-phase nature of transport in tumors. Nat. Med. 10, 203-207 (2004).
49. R. G. Thorne, A. Lakkaraju, E. Rodriguez-Boulan, C. Nicholson, In vivo diffusion of lactoferrin in brain extracellular space is regulated by interactions with heparan sulfate. Proc. Natl. Acad. Sci. U.S.A. 105, 8416-8421 (2008).
50. R. K. Sironen, M. Tammi, R. Tammi, P. K. Auvinen, M. Antilla, V.-M. Kosma, Hyaluronan in human malignancies. Exp. Cell Res. 317, 383-391 (2011).
51. B. P. Toole, Hyaluronan: From extracellular glue to pericellular cue. Nat. Rev. Cancer 4, 528-539 (2004).
52. R. Sasisekharan, Z. Shriver, G. Venkataraman, U. Narayanasami, Roles of heparan-sulphate glycosaminoglycans in cancer. Nat. Rev. Cancer 2, 521-528 (2002).
53. E. O. Kozlowski, M. S. Pavao, Effect of sulfated glycosaminoglycans on tumor invasion and metastasis. Front. Biosci. 3, 1541-1551 (2011).
54. K. Ropponen, M. Tammi, J. Parkkinen, M. Eskelinen, R. Tammi, P. Lipponen, U. Ågren, E. Alhava, V.-M. Kosma, Tumor cell-Associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res. 58, 342-347 (1998).
55. P. Auvinen, R. Tammi, J. Parkkinen, M. Tammi, U. Ågren, R. Johansson, P. Hirvikoski, M. Eskelinen, V.-M. Kosma, Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am. J. Pathol. 156, 529-536 (2000).
56. R. Pirinen, R. Tammi, M. Tammi, P. Hirvikoski, J. J. Parkkinen, R. Johansson, J. Böhm, S. Hollmén, V.-M. Kosma, Prognostic value of hyaluronan expression in non-small-cell lung cancer: Increased stromal expression indicates unfavorable outcome in patients with adenocarcinoma. Int. J. Cancer 95, 12-17 (2001).
57. R. H. Tammi, A. Kultti, V.-M. Kosma, R. Pirinen, P. Auvinen, M. I. Tammi, Hyaluronan in human tumors: Pathobiological and prognostic messages from cell-Associated and stromal hyaluronan. Semin. Cancer Biol. 18, 288-295 (2008).
58. C. Wang, M. Tammi, H. Guo, R. Tammi, Hyaluronan distribution in the normal epithelium of esophagus, stomach, and colon and their cancers. Am. J. Pathol. 148, 1861-1869 (1996).
59. S. Ghatak, S. Misra, B. P. Toole, Hyaluronan oligosaccharides inhibit anchorageindependent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J. Biol. Chem. 277, 38013-38020 (2002).
60. R. Kosaki, K. Watanabe, Y. Yamaguchi, Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage-independent growth and tumorigenicity. Cancer Res. 59, 1141-1145 (1999).
61. A. Zoltan-Jones, L. Huang, S. Ghatak, B. P. Toole, Elevated hyaluronan production induces mesenchymal and transformed properties in epithelial cells. J. Biol. Chem. 278, 45801-45810 (2003).
62. Y. Fujita, M. Kitagawa, S. Nakamura, K. Azuma, G. Ishii, M. Higashi, H. Kishi, T. Hiwasa, K. Koda, N. Nakajima, K. Harigaya, CD44 signaling through focal adhesion kinase and its anti-Apoptotic effect. FEBS Lett. 528, 101-108 (2002).
63. C. L. Hall, C. Wang, L. A. Lange, E. A. Turley, Hyaluronan and the hyaluronan receptor RHAMM promote focal adhesion turnover and transient tyrosine kinase activity. J. Cell Biol. 126, 575-588 (1994).
64. Q. Yu, I. Stamenkovic, Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev. 13, 35-48 (1999).
65. L. Y. Bourguignon, Z. Gunja-Smith, N. Iida, H. B. Zhu, L. J. Young, W. J. Muller, R. D. Cardiff, CD44v3,8-10 is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J. Cell. Physiol. 176, 206-215 (1998).
66. S. Koochekpour, G. J. Pilkington, A. Merzak, Hyaluronic acid/CD44H interaction induces cell detachment and stimulates migration and invasion of human glioma cells in vitro. Int. J. Cancer 63, 450-454 (1995).
67. N. Itano, T. Sawai, O. Miyaishi, K. Kimata, Relationship between hyaluronan production and metastatic potential of mouse mammary carcinoma cells. Cancer Res. 59, 2499-2504 (1999).
68. Q. Yu, B. P. Toole, I. Stamenkovic, Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J. Exp. Med. 186, 1985-1996 (1997).
69. P. Lipponen, S. Aaltomaa, R. Tammi, M. Tammi, U. Ågren, V.-M. Kosma, High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer. Eur. J. Cancer 37, 849-856 (2001).
70. S. R. Hingorani, W. P. Harris, J. T. Beck, B. A. Berdov, S. A. Wagner, E. M. Pshevlotsky, S. A. Tjulandin, O. A. Gladkov, R. F. Holcombe, R. Korn, N. Raghunand, S. Dychter, P. Jiang, H. M. Shepard, C. E. Devoe, Phase Ib study of PEGylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer. Clin. Cancer Res. 22, 2848-2854 (2016).
71. N. Ding, R. T. Yu, N. Subramaniam, M. H. Sherman, C. Wilson, R. Rao, M. Leblanc, S. Coulter, M. He, C. Scott, S. L. Lau, A. R. Atkins, G. D. Barish, J. E. Gunton, C. Liddle, M. Downes, R. M. Evans, A Vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell 153, 601-613 (2013).
72. M. H. Sherman, R. T. Yu, D. D. Engle, N. Ding, A. R. Atkins, H. Tiriac, E. A. Collisson, F. Connor, T. Van Dyke, S. Kozlov, P. Martin, T. W. Tseng, D. W. Dawson, T. R. Donahue, A. Masamune, T. Shimosegawa, M. V. Apte, J. S. Wilson, B. Ng, S. Lynn Lau, J. E. Gunton, G. M. Wahl, T. Hunter, J. A. Drebin, P. J. O'Dwyer, C. Liddle, D. A. Tuveson, M. Downes, R. M. Evans, Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 159, 80-93 (2014).
73. B. A. Tannous, Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo. Nat. Protoc. 4, 582-591 (2009).
74. E. Chung, H. Yamashita, P. Au, B. A. Tannous, D. Fukumura, R. K. Jain, Secreted Gaussia luciferase as a biomarker for monitoring tumor progression and treatment response of systemic metastases. PLOS ONE 4, e8316 (2009).
75. R. L.-Y. Sah, Y.-J. Kim, J.-Y. Doong, A. J. Grodzinsky, A. H. K. Plaas, J. D. Sandy, Biosynthetic response of cartilage explants to dynamic compression. J. Orthop. Res. 7, 619-636 (1989).
76. J. Woessner Jr., The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch. Biochem. Biophys. 93, 440-447 (1961).
77. P. A. Netti, D. A. Berk, M. A. Swartz, A. J. Grodzinsky, R. K. Jain, Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 60, 2497-2503 (2000).
78. T. Sugaya, S.-i. Nishimatsu, K. Tanimoto, E. Takimoto, T. Yamagishi, K. Imamura, S. Goto, K. Imaizumi, Y. Hisada, A. Otsuka, H. Uchida, M. Sugiura, K. Fukuta, A. Fukamizu, K. Murakami, Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J. Biol. Chem. 270, 18719-18722 (1995).